Cracks Are Forming in Cronos Group Stock
Todd Shriber, 28 March 2019
As has been widely noted since the start of the year, marijuana equities are among 2019’s best-performing issues. Until recently, it would have been accurate to include Cronos Group (NASDAQ:CRON) in that conversation. Although the ides of March recently struck Cronos Group stock, shares of the Canadian cannabis company are still up 94.80% this year (as of March 27). In fact, Wednesday could go down as a day of infamy for Cronos Group stock.
In late trading, CRON stock was down more than 11% on above-average volume after Canaccord Genuity analysts Matt Bottomley and Bobby Burleson downgraded the shares to “sell” from “hold.” Late Wednesday, Cronos Group stock was clinging to the $18 area, well above Canaccord’s price target of $12.68. “While the sales of Canada’s other prominent producers ranged from $15 million to $60 million in the December quarter — the first in which the country allowed recreational sales to adults — Cronos managed just $4 million in sales of both medical and recreational pot,” reports Barron’s. “That even missed the low-bar of Canaccord’s forecast for $5 million.”
Continue reading “Article: Cracks Are Forming in Cronos Group Stock”
